Patient 1 2 3 4
Age (y) 60 59 63 55
Gender Male Male Male Male
Diagnosis MM MM MDS MM
Conditioning treatment TBI (2 Gy) Fludarabine, Cyclofosfamide Fludarabine, TBI (2 Gy) TBI (2 Gy)
Allo-RIC donor HLA-matched sibling HLA identical sibling HLA identical sibling HLA identical sibling
Serum triglycerides (mmol/L) at baseline 2.9 2.1 4.7 2.2
Body weight (kg) 82.0 74.7 68.4 96.8
Diarrhoea (mL/24 h) 1000 500 500-1000 700
GVHD Liver B A B A
GVHD Skin A A A A
Amylase (U/L)1 102 95 34 70
Lipase (U/L)1 56 26 28 42
ALAT (U/L)1 94 63 112 131
ASAT (U/L)1 39 82 72 70
GGT (<U/L)1 776 300 1139 307
AP (U/L)1 165 177 212 99
MM: Multiple Myeloma; MDS: Myelodysplastic Syndrome; TBI: Total Body Irradiation; RIC: Reduced Intensity Conditioning stem cell transplantation; HLA: Human Leukocyte Antigen; GVHD: Graft-Versus-Host Disease; ALAT: Alanine Aminotransferase; ASAT: Aspartate Aminotransferase; GGT: Gamma Glutamyl Transferase; AP: Alkaline Phosphatase.
1Reference values: amylase: <100 U/L, lipase: <70 U/L, ALAT: <50 U/L, ASAT: <45 U/L, GGT: <45 U/L, AP: <125 U/L.
Table 1: Baseline characteristics of 4 patients with chronic GVHD-DT grade B.